All individual trials at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trials reported
65 out of 65
Percent reported
100.0%
US Govt could have imposed fines of at least
$42,747,455
Fines claimed by US Govt
$0
Showing 1 to 100 of 136 entries
Status | Sponsor | Trial ID | Title | Completion date | Days overdue |
---|---|---|---|---|---|
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01578551 | A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Previously Untreated Advanced/Metastatic Pulmonary Adenocarcinoma [pACT] | 2017-01-31 | 230 |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02111174 | A Pilot Randomized Sham-Controlled Trial of MC5-A Calmare Therapy (Scrambler Therapy) in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN) [pACT] | 2017-03-24 | 90 |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02080195 | A Phase I/II Study of Nonmyeloablative Conditioning and Transplantation of Human Leukocyte Antigen (HLA)-Matched, Partially HLA-mismatched, HLA-haploidentical or Matched Unrelated Bone Marrow for Patients With Refractory SLE [pACT] | 2017-03-28 | 162 |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02096588 | Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin [pACT] | 2017-04-25 | 384 |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01588951 | Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior [pACT] | 2017-04-30 | |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02243371 | A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS-207 With or Without Nivolumab in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma [pACT] | 2017-07-21 | 381 |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01696877 | A Neoadjuvant Immunologic Study of Androgen Deprivation Therapy Combined With a Granulocytemacrophage-colony Stimulating Factor F-secreting Allogeneic Prostate Cancer Vaccine and Low-dose Cyclophosphamide in Men With High-risk Localized Prostate Cancer Undergoing Radical Prostatectomy [pACT] | 2017-08-31 | 28 |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT00363649 | A Randomized Phase II Trial of Interferon + GM-CSF Versus K562/GM-CSF Vaccination in CML Patients Achieving a Complete Cytogenetic Response to Frontline Tyrosine Kinase Inhibitor Therapy [pACT] | 2017-09-30 | 10 |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01665768 | A Trial of Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in CD20+, B-cell Lymphomas, Gray Zone Lymphoma, and Hodgkin's Lymphoma [pACT] | 2017-10-31 | 9 |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02489357 | A Pilot Study of MK-3475 With Cryotherapy for Men With Newly Diagnosed Oligo-metastatic Prostate Cancer [pACT] | 2017-11-30 | 98 |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01088815 | A Phase II Study of Gemcitabine and Nab-Paclitaxel in Combination With GDC-0449 (Hedgehog Inhibitor) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas [pACT] | 2017-12-01 | 122 |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02981524 | A Phase 2 Study of GVAX Colon Vaccine (With Cyclophosphamide) and Pembrolizumab in Patients With Mismatch Repair-Proficient (MMR-p) Advanced Colorectal Cancer | 2018-03-20 | 162 |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01937117 | A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer [pACT] | 2018-03-20 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02491411 | A Pilot Study of Dexamethasone Therapy Prior to Rechallenge With Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer Dex EXTends Enza Response (The DEXTER Trial) [pACT] | 2018-03-31 | |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01752036 | Phase II Study of Post-Operative Stereotactic Radiosurgery for Solid Tumor Spine Metastases [pACT] | 2018-04-02 | 430 |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03218163 | A Phase II Study of MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Patients With Newly Diagnosed Poor-risk or Relapsed Multiple Myeloma | 2018-04-15 | |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01478854 | A Prospective Trial of Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide for Newly Diagnosed Glioblastoma Multiforme [pACT] | 2018-04-25 | 28 |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02120157 | Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies [pACT] | 2018-06-15 | |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02680587 | Phase II Randomized Observation Versus Stereotactic Ablative RadiatIOn for OLigometastatic Prostate CancEr (ORIOLE) Trial [pACT] | 2018-08-30 | 690 |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02864316 | Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure [pACT] | 2018-08-31 | |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01763970 | A Phase II Study of Hyperfractionated Stereotactic Radiotherapy in the Treatment of Metastatic Pediatric Sarcomas of Bony Sites [pACT] | 2018-09-24 | 324 |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02286921 | A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer [pACT] | 2018-10-26 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01431794 | Phase 1/2 Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma. [pACT] | 2018-11-05 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT00489281 | A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Anemia and Other Hemoglobinopathies [pACT] | 2018-12-29 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01896869 | A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination With Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer [pACT] | 2019-05-03 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01858558 | Randomized Phase II Study of Autologous Stem Cell Transplantation With Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma [pACT] | 2019-06-19 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02324543 | Phase 1/2 Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer [pACT] | 2019-06-30 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01896856 | A Phase I Study of SGI-110 Combined With Irinotecan Followed by a Randomized Phase II Study of SGI-110 Combined With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer Patients [pACT] | 2019-08-26 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01876511 | Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors [pACT] | 2019-08-31 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03216499 | Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma | 2019-08-31 | |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01088802 | A Phase II Study on Treatment De-Intensification in Favorable Squamous Cell Carcinoma of the Oropharynx [pACT] | 2019-10-31 | 713 |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02463799 | A Phase 2 Study of Sipuleucel-T With or Without Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer [pACT] | 2019-12-12 | 185 |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03091478 | Pembrolizumab in Patients With Leptomeningeal Disease | 2019-12-14 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01728779 | Single-Arm Phase II Study of Stereotactic Body Radiation Therapy Concurrent With Nelfinavir for Oligometastases [pACT] | 2020-03-31 | |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01700673 | A Phase II Study of 5-Azacitidine (5AC) in Combination With Sargramostim (GM-CSF) as Maintenance Treatment, After Definitive Therapy With Either Stem Cell Transplant (SCT) or Cytarabine-based Chemotherapy, in Patients With Poor-risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [pACT] | 2020-06-30 | 37 |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02923180 | A Phase II Trial of Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate- and High-Risk Prostate Cancer | 2020-08-11 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03886493 | Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer | 2020-10-06 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03250273 | A Phase 2 Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | 2020-11-20 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02601014 | Biomarker-Driven Phase-2 Study of Combined Immune Checkpoint Blockade for AR-V7-Expressing Metastatic Castration-Resistant Prostate Cancer (STARVE-PC) [pACT] | 2020-12-03 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03863522 | Automated Method for Breast Cancer Detection | 2020-12-15 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01845805 | A Phase II Trial to Improve Outcomes in Patients With Resected Pancreatic Adenocarcinoma at High Risk for Recurrence Using Epigenetic Therapy [pACT] | 2021-04-09 | |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02556931 | Phase II Study of Shortened-duration Tacrolimus Following Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Malignancies That Are Challenging to Engraft [pACT] | 2021-04-30 | 137 |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02833805 | A Phase II Trial of Non-Myeloablative (NMA) Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Donor (MUD) Bone Marrow for Newly Diagnosed Patients With Severe Aplastic Anemia [pACT] | 2021-07-31 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02516670 | A Randomized Phase 2 Trial of Ascorbic Acid in Combination With Docetaxel in Men With Metastatic Prostate Cancer [pACT] | 2021-07-31 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02017704 | Chemoradiation OR Brachytherapy for RECTal Cancer [pACT] | 2021-09-30 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT00389610 | A Safety and Efficacy Trial of Vaccine Boosting With Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma [pACT] | 2021-10-11 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03237377 | Neoadjuvant Immunoradiation for Stage III Resectable Non-Small Cell Lung Cancer | 2021-11-04 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02090114 | A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) Followed by Enzalutamide or Abiraterone Post-BAT in Men With Prostate Cancer Progressing on Combined Androgen Ablative Therapies [pACT] | 2021-11-11 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03420521 | An Open-Label, Single Arm Phase II Study of Nivolumab in Combination With Ipilimumab in Subjects With Advanced Neuroendocrine Tumors | 2021-11-24 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03307564 | Evaluation of a Novel Absorbable Radiopaque Hydrogel in Patients Undergoing Image-guided Radiotherapy for Pancreatic Adenocarcinoma | 2021-12-31 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01466686 | A Phase II Trial of Low Dose Fractionated Radiation Therapy as a Chemo-Potentiator of Salvage Temozolomide for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme [pACT] | 2021-12-31 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02845297 | Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (≥65 Years) AML Patients [pACT] | 2022-04-30 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02716974 | A Phase II Study of Definitive Therapy for Newly Diagnosed Men With Oligometastatic Prostate Cancer [pACT] | 2022-04-30 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT04098068 | Phase 2 Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors | 2022-05-15 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02648282 | A Phase II Study of GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine in Combination With PD-1 Blockade Antibody (Pembrolizumab) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Locally Advanced Adenocarcinoma of the Pancreas [pACT] | 2022-06-01 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03711058 | A Phase I/II Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | 2022-06-14 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03535675 | A Randomized Double-Blind, Placebo-Controlled Study Of The Effects Of MPX Capsules On Rising Prostate-Specific Antigen Levels In Alanine/Alanine SOD2 Genotype Men Following Initial Therapy For Prostate Cancer | 2022-07-06 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03190265 | A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cyclophosphamide) in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma | 2022-08-03 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03535727 | A Phase I/II Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Combination in Metastatic Pancreatic Cancer | 2022-10-03 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT04386746 | A Phase II Trial for the Use of Intravesical Gemcitabine and Docetaxel (GEMDOCE) in the Treatment of BCG naïve Non-muscle Invasive Urothelial Carcinoma of the Bladder | 2022-10-04 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02259621 | Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer. [pACT] | 2022-10-14 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03043807 | A Phase II Study of Definitive Therapy for Newly Diagnosed Men With Oligometastatic Prostate Cancer After Prostatectomy | 2022-10-17 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03554317 | COMbination of Bipolar Androgen Therapy and Nivolumab in Patients With Metastatic Castration-Resistant Prostate Cancer | 2022-10-27 | |
reported | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT04301778 | A Phase II Study of Durvalumab (MEDI4736) in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma. | 2022-11-04 | |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02203695 | Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy [pACT] | 2022-12-31 | 23 |
reported-late | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03603002 | Studying the Pathologic and Immunologic Response After Ablative Radiation in Stage I Non-Small Cell Lung Cancer | 2022-12-31 | 29 |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT04177810 | A Phase 2 Study of Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer | 2023-03-29 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01928576 | A Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab in Subjects With Metastatic Non-Small Cell Lung Cancer. [pACT] | 2023-04-04 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03047135 | Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis | 2023-05-24 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03006302 | Phase 2 Study of Epacadostat, Pembrolizumab, and CRS-207, With or Without Cyclophosphamide and GVAX Pancreas Vaccine in Patients With Metastatic Pancreas Cancer | 2023-08-22 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03573648 | A Pilot Study of IMMUNe mOdulation in Early Stage Estrogen Receptor Positive Breast Cancer Treated With neoADjuvant Avelumab, Palbociclib, and Endocrine Therapy: The ImmunoADAPT Study | 2023-12-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03413995 | Phase II Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH) | 2023-12-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03914742 | Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations | 2023-12-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT04499950 | A Phase II Single Arm Adaptive Weight Loss Study in Women With Early Stage Breast Cancer | 2023-12-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03439735 | Prospective Evaluation of Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor in Hormone Receptor (HR) Positive Metastatic Breast Cancer (MBC) | 2024-03-01 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03376477 | A Randomized, Double-blind, Placebo-Controlled Phase II Trial of an Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission | 2024-03-17 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03786796 | Phase II Study of Olaparib in Metastatic Renal Cell Carcinoma Patients Harboring a BAP-1 or Other DNA Repair Gene Mutations (ORCHID) | 2024-03-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT04848116 | Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Cancer Patients Undergoing Surgery | 2024-04-30 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03914794 | Phase 2 Window of Opportunity Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors | 2024-05-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02452008 | Overcoming Drug Resistance in Metastatic Castration-resistant Prostate Cancer With Novel Combination of TGF-β Receptor Inhibitor LY2157299 and Enzalutamide: a Randomized Multi-site Phase II Study [pACT] | 2024-06-30 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT05312671 | Atezolizumab With Platinum and Etoposide Chemotherapy Followed by Cystectomy for Patients With Localized Small Cell Neuroendocrine Bladder Cancer | 2024-06-30 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT04209686 | Phase 2 Study of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma | 2024-07-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02738866 | Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor [pACT] | 2024-07-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03878979 | Preoperative Immune Checkpoint Inhibitor Therapy for Patients With Primary Untreated or Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN) | 2024-07-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT02845323 | Randomized Phase II Study of Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder | 2024-07-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01088789 | A Safety and Feasibility Trial of Boost Vaccinations of a Lethally Irradiated, Allogeneic Pancreatic Tumor Cell Vaccine Transfected With the GM-CSF Gene [pACT] | 2024-08-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01595321 | Pilot Study Evaluating An Allogeneic GM-CSF-Transduced Pancreatic Tumor Cell Vaccine (GVAX) and Low Dose Cyclophosphamide Integrated With Fractionated Stereotactic Body Radiation Therapy (SBRT) and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas [pACT] | 2024-09-30 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03638141 | The Effect of CTLA-4/PD-L1 Blockade Following Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC Using Durvalumab (MEDI4736) and Tremelimumab | 2024-09-30 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT04117074 | A Non-Inferiority Randomized Trial Comparing the Impact of Thoracic Epidural Analgesia Versus Surgical Site Infiltration With Liposomal Bupivicaine on the Postoperative Recovery of Patients Following Open Gynecologic Surgery | 2024-09-30 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03161379 | A Phase II Clinical Trial of GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With Nivolumab and Stereotactic Body Radiation Therapy (SBRT) Followed by Definitive Resection for Patients With Borderline Resectable Pancreatic Adenocarcinoma | 2024-09-30 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03607890 | Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor | 2024-10-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT04988074 | A Phase II Trial of Cemiplimab, or Cemiplimab-Chemotherapy, Followed by Biomarker-guided De-escalated Curative-intent Locoregional Treatment for Patients With Advanced HPV-related Head and Neck Cancer. The MINIMA Study | 2024-11-30 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03521830 | Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma | 2024-11-30 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT05014776 | A Phase 2 Study of the Safety, Efficacy, and Immune Response of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma | 2024-12-01 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03727880 | A Randomized Phase II Study of Pembrolizumab With or Without Defactinib, a Focal Adhesion Kinase Inhibitor Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (PDAC) | 2024-12-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT04116073 | A Phase II Trial of INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer | 2024-12-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03767582 | A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs). | 2024-12-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03610711 | REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer | 2024-12-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT01517451 | Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate [pACT] | 2024-12-31 | |
ongoing | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT03043794 | A Phase II Study of Preoperative Single Fraction Stereotactic Body Radiotherapy to the Intact Breast in Early Stage Low Risk Breast Cancer: Analysis of Radiation Response | 2024-12-31 |